乙型肝炎特殊人群抗病毒治疗的新认识

胡晓云; 孙剑; 彭劼

doi:10.3969/j.issn.1001-5256.2016.11.007

乙型肝炎特殊人群抗病毒治疗的新认识

DOI: 10.3969/j.issn.1001-5256.2016.11.007

南方医科大学南方医院感染内科暨肝病中心

详细信息

中图分类号: R512.62
计量
- 文章访问数: 2440
- HTML全文浏览量: 18
- PDF下载量: 496
- 被引次数: 0
出版历程
- 出版日期: 2016-11-20

New considerations in antiviral therapy for special populations with chronic hepatitis B

摘要

摘要:
在慢性乙型肝炎人群中,合并HIV/HCV/HDV感染、儿童和青少年、妊娠妇女、慢性肾损害、应用化疗和免疫抑制剂等特殊人群的抗病毒治疗问题日益受到重视。关于乙型肝炎特殊人群的抗病毒治疗指征、药物选择及调整、抗病毒疗程等是目前临床研究的热点。近几年各大乙型肝炎防治指南均提出要规范乙型肝炎特殊人群的管理,但对该人群抗病毒治疗的推荐证据级别不高。临床工作中应结合现有的研究成果,规范管理流程,力求建立高质量的队列研究,以获得强有力的循证医学证据,更好的指导临床治疗。
- 肝炎,乙型,慢性 /
- 抗病毒药 /
- 治疗
Abstract:
Increasing attentions have been paid to the antiviral therapy for special populations with chronic hepatitis B( CHB),including patients co- infected with HIV,HDV,or HCV,children and adolescents,pregnant women,patients with chronic kidney diseases,and patients who require chemotherapy or immunosuppressive therapy. The indications for antiviral therapy,drug selection and adjustment,and treatment course in special populations with CHB have become the hot topics of clinical research. In recent years,all guidelines for the prevention and treatment of CHB have provided a summary of key considerations in the standardized management of these populations. However,the strength of recommendations for antiviral therapy in these populations is not high. In order to obtain a strong medical evidence for antiviral therapy in these populations,we should standardize clinical management processes and carry out high- quality cohort studies based on the previous research.
- hepatitis B,chronic /
- antiviral agents /
- therapy

HTML全文

参考文献(32)

[1]Geneva:World Health Organization.Guidelines for the Prevention,Care and Treatment of Persons with Chronic Hepatitis B Infection[S/OL].World Health Organization,2015[2016-08-26].https://www.ncbi.nlm.nih.gov/books/NBK305553/.

[2]European Association for the Study of the Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.

[3]TANG CM,YAU TO,YU J.Management of chronic hepatitis B infection:current treatment guidelines,challenges,and new developments[J].World J Gastroenterol,2014,20(20):6262-6278.

[4]SARIN SK,KUMAR M,LAU GK,et al.Asian-Pacific clinical practice guidelines on the management of hepatitis B:a2015 update[J].Hepatol Int,2016,10(1):1-98.

[5]TERRAULT NA,BZOWEJ NH,CHANG KM,et al.AASLD guidelines for treatment of chronic hepatitis B[J].Hepatology,2016,63(1):261-283.

[6]PARK JS,PAN C.Current recommendations of managing HBV infection in preconception or pregnancy[J].Front Med,2014,8(2):158-165.

[7]LUO Z,LI L,RUAN B.Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period[J].Int J Infect Dis,2012,16(2):e82-e88.

[8]ZHANG L,GUI X,WANG B,et al.A study of immunoprophylaxis failure and risk factors of hepatitis B virus mother-to-infant transmission[J].Eur J Pediatr,2014,173(9):1161-1168.

[9]BROWN RS Jr,McM AHON BJ,LOK AS,et al.Antiviral therapy in chronic hepatitis B viral infection during pregnancy:a systematic review and meta-analysis[J].Hepatology,2016,63(1):319-333.

[10]PAN CQ,DUAN Z,DAI E,et al.Tenofovir to prevent hepatitis B transmission in mothers with high viral load[J].N Engl J Med,2016,374(24):2324-2334.

[11]BROWN RS Jr,VERNA EC,PEREIRA MR,et al.Hepatitis B virus and human immunodeficiency virus drugs in pregnancy:findings from the antiretroviral pregnancy registry[J].J Hepatol,2012,57(5):953-959.

[12]SIBERRY GK,JACOBSON DL,KALKWARF HJ,et al.Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy[J].Clin Infect Dis,2015,61(6):996-1003.

[13]The antiretroviral pregnancy registry——interim report[R/OL].(2016-06)[2016-08-26].http://www.apregistry.com/forms/interim_report.pdf.

[14]HU Y,CHEN J,WEN J,et al.Effect of elective cesarean section on the risk of mother-to-child transmission of hepatitis B virus[J].BMC Pregnancy Childbirth,2013,13:119.

[15] LIU CP,ZENG YL,ZHOU M,et al.Factors associated with mother-to-child transmission of hepatitis B virus despite immunoprophylaxis[J].Intern Med,2015,54(7):711-716.

[16]YANG J,ZENG XM,MEN YL,et al.Elective caesarean section versus vaginal delivery for preventing mother to child transmission of hepatitis B virus——a systematic review[J].Virol J,2008,5:100.

[17]PAN CQ,ZOU HB,CHEN Y,et al.Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants[J].Clin Gastroenterol Hepatol,2013,11(10):1349-1355.

[18]EHRHARDT S,XIE C,GUO N,et al.Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate:a review of the evidence[J].Clin Infect Dis,2015,60(2):275-278.

[19]PETROVA M,KAMBUROV V.Breastfeeding and chronic HBV infection:clinical and social implications[J].World J Gastroenterol,2010,16(40):5042-5046.

[20] ZHANG L,WANG F,WANG L,et al.Prevalence of chronic kidney disease in China:a cross-sectional survey[J].Lancet,2012,379(9818):815-822.

[21]FUNG J,SETO WK,LAI CL,et al.Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment[J].J Gastroenterol Hepatol,2014,29(3):428-434.

[22]FONTANA RJ.Side effects of long-term oral antiviral therapy for hepatitis B[J].Hepatology,2009,49(5 Suppl):s185-s195.

[23]FLEISCHER RD,LOK AS.Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B[J].J Hepatol,2009,51(4):787-791.

[24]CHEN YC,SU YC,LI CY,et al.13-year nationwide cohort study of chronic kidney disease risk among treatment-naive patients with chronic hepatitis B in Taiwan[J].BMC Nephrol,2015,16:110.

[25]LIU Y,FAN R,CHEN J,et al.Assessment of renal function and risk factors for renal impairment in patients with hepatitis B virus-related liver cirrhosis[J].J South Med Univ,2014,34(4):472-476.(in Chinese)刘颖,樊蓉,陈简,等.慢性乙型肝炎病毒感染相关肝硬化患者的肾功能及危险因素分析[J].南方医科大学学报,2014,34(4):472-476.

[26]LING N,LIN WY,HU XY,et al.Prevalence of chronic kidney disease in patients with chronic hepatitis B who are on antiviral therapy:a cross-sectional survey[C].25th APASL STC,Tokyo,2016.

[27]PIPILI C,CHOLONGITAS E,PAPATHEODORIDIS G.Review article:nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease[J].Aliment Pharmacol Ther,2014,39(1):35-46.

[28]JIA HY,DING F,CHEN JY,et al.Early kidney injury during long-term adefovir dipivoxil therapy for chronic hepatitis B[J].World J Gastroenterol,2015,21(12):3657-3662.

[29]GANE EJ,DERAY G,LIAW YF,et al.Telbivudine improves renal function in patients with chronic hepatitis B[J].Gastroenterology,2014,146(1):138-146,e135.

[30]LEE M,OH S,LEE HJ,et al.Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy[J].J Viral Hepat,2014,21(12):873-881.

[31]CHOLONGITAS E,VASILIADIS T,GOULIS I,et al.Telbivudine is associated with improvement of renal function in patients transplanted for HBV liver disease[J].J Viral Hepat,2015,22(7):574-580.

[32]HWANG JP,LOK AS.Management of patients with hepatitis B who require immunosuppressive therapy[J].Nat Rev Gastroenterol Hepatol,2014,11(4):209-219.

施引文献

资源附件(0)

访问统计